中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (7): 567-573.doi: 10.19401/j.cnki.1007-3639.2021.07.002

• 专家述评 • 上一篇    下一篇

分化好的胃肠胰神经内分泌瘤G3的诊治新进展

高鹤丽,徐 近,虞先濬   

  1. 复旦大学附属肿瘤医院胰腺外科,复旦大学上海医学院肿瘤学系,复旦大学胰腺肿瘤研究所,上海市胰腺肿瘤研究所,上海 200032
  • 出版日期:2021-07-30 发布日期:2021-08-03
  • 通信作者: 虞先濬 E-mail: yuxianjun@fudanpci.org

Advances in clinical diagnosis and treatment of gastroenteropancreatic neuroendocrine tumor G3

GAO Heli, XU Jin, YU Xianjun   

  1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute, Shanghai 200032, China
  • Published:2021-07-30 Online:2021-08-03
  • Contact: YU Xianjun E-mail: yuxianjun@fudanpci.org

摘要: 神经内分泌肿瘤属于少见肿瘤,发病率低,异质性强,可发生于全身多个器官。在中国,胃肠胰是神经内分泌肿瘤发病率最高的部位,自2017年世界卫生组织(World Health Organization,WHO)消化系统肿瘤病理学分类关于胃肠胰神经内分泌肿瘤提出分化好的神经内分泌瘤G3(neuroendocrine tumor G3,NET G3)的概念后,分化好的NET G3的相关研究日益增多。对分化好的胃肠胰NET G3的诊治新进展进行综述。

关键词: 神经内分泌瘤, 高分级, 治疗进展, 预后

Abstract: Neuroendocrine neoplasms are rare and heterogenous, with low incidence, which can occur in multiple organs of the body. Gastroenteropancreatic neuroendocrine neoplasms have the highest incidence in China. 2017 version World Health Organization (WHO) classification of gastroenteropancreatic neuroendocrine neoplasms put forward the concept of well- differentiated neuroendocrine tumors (NET) G3. The related research has started to increase. This article reviewed the latest advances in clinical diagnosis and treatment of well-differentiated gastroenteropancreatic NET G3.

Key words: Neuroendocrine tumor, High-grade, Treatment progress, Prognosis